LETTER FROM THE CHAIR
Dear Colleagues:
It is our pleasure to welcome you to this virtual conference, the 13th Annual T-Cell Lymphoma Forum. This important innovative experience will take you on a unique learning journey, which begins when you enter the Virtual Conference Center.
The comprehensive agenda includes the most relevant topics that impact the hematology/oncology practice today. At a glance, these are:
- Epidemiology and Classification
- Molecular Biology and Pathogenesis
- T-Cell Lymphoma Subtypes
- Treatment
- Cutaneous T-Cell Lymphoma
- International Guidelines
- Industry Innovations
Our internationally renowned faculty will engage you as you take a seat in the Live Theater. Following each session, there will be ample time for your questions to be addressed.
As with any live conference, you will find additional opportunities to interact with your colleagues beyond the sessions. We invite you to explore the Virtual Poster Hall, network in the Lounge, and visit the Exhibit Hall.
Each of the presentations will be prerecorded and if you miss one or just need a refresher, you will be able to go back to the educational theater and watch it again. Some, if not all slides will be available for downloading as PDFs.
Once again, we look forward to welcoming you to this important educational activity.
Sincerely,
Francine M. Foss, MD
Co-Chair
Professor of Medicine
Section of Medical Oncology
Yale University School of Medicine
Smilow Cancer Center
New Haven, CT
Won Seog Kim, MD, PhD
Co-Chair
Professor Division of Hematology/Oncology
Samsung Medical Center
Sungkyunkwan University
School of Medicine
Seoul, Republic of Korea
Owen A. O’Connor, MD, PhD
Co-Chair
American Cancer Society
Research Professor
Director, Program for T-cell Lymphoma
Department of Medicine
Division of Hematology and Oncology
University of Virginia Cancer Center
Charlottesville, VA
AGENDA
Select a date below to view more details.
JULY 8
JULY 9
JULY 10
CHAIRS
CME/CE credit is not available for this virtual event.
TARGET AUDIENCE
This meeting is intended for hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphomas.
LEARNING OBJECTIVES
After attending meeting, participants will be able to: [LIST] [ITEM]Summarize recent data to update the epidemiology and classification of T-cell lymphoma [ITEM]Assess new molecular insights into the pathogenesis of T-cell lymphoma [ITEM]Examine updates in further characterization of various subtypes of T-cell lymphoma [ITEM]Appraise novel approaches in the treatment of T-cell lymphoma [ITEM]Deliberate on recent progress in cutaneous T-cell lymphoma [ITEM]Discuss the similarities and differences in T-cell lymphoma management guidelines from all over the world [ITEM]Evaluate cutting-edge innovations pertinent to T-cell lymphoma [ITEM]Design strategies to implement updates in T-cell lymphoma management [/LIST]